 Elevation Oncology Inc NASDAQ: ELEV shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions. Seribantumab. 